U.S - FDA Approves Expanded Pediatric Indication for Biktarvy

FDA granted the approval of a new low-dose tablet dosage form of Biktarvy expanding the pediatric indication to treat younger children living with HIV who weigh at least 14kg and are virologically suppressed or new to antiretroviral therapy. The new formulation will help to close the gap between HIV treatment options available for adults and children and stands as a significant milestone with the potential to save many lives.

This approval marks important progress towards Gilead’s continued commitment to help end the HIV epidemic for everyone, everywhere.